Concert Pharmaceuticals (NASDAQ:CNCE) Receiving Positive News Coverage, Accern Reports
Media stories about Concert Pharmaceuticals (NASDAQ:CNCE) have been trending positive on Friday, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Concert Pharmaceuticals earned a daily sentiment score of 0.30 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.2355125890476 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Shares of Concert Pharmaceuticals (NASDAQ CNCE) opened at $22.46 on Friday. Concert Pharmaceuticals has a 1 year low of $11.88 and a 1 year high of $30.71.
Concert Pharmaceuticals (NASDAQ:CNCE) last posted its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.08). Concert Pharmaceuticals had a net margin of 66.47% and a negative return on equity of 36.25%. The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $8.11 million. analysts forecast that Concert Pharmaceuticals will post -2.35 EPS for the current fiscal year.
In other Concert Pharmaceuticals news, Director Richard Aldrich sold 11,946 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $20.89, for a total transaction of $249,551.94. Following the completion of the sale, the director now owns 286,975 shares of the company’s stock, valued at $5,994,907.75. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Value Fund L. P. Biotechnology sold 1,282,856 shares of the business’s stock in a transaction dated Tuesday, December 19th. The shares were sold at an average price of $26.65, for a total value of $34,188,112.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,419,092 shares of company stock valued at $36,876,675. 10.10% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: This news story was published by Marea Informative and is the sole property of of Marea Informative. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.mareainformativa.com/2018/03/16/concert-pharmaceuticals-cnce-earns-daily-news-impact-score-of-0-30-updated-updated-updated.html.
Concert Pharmaceuticals Company Profile
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.